Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
DeepBiome Therapeutics
AddedFeb 16, 2024
UpdatedJun 18, 2026
DeepBiome Therapeutics

DeepBiome Therapeutics

Seed

DeepBiome Therapeutics, a US-based biotech firm, leverages deep learning and synthetic biology for innovative drug discovery.

HQ
Llanura, MA, US
Founded
2017
Overview
Compare
Fundraising
Employees

Founded in 2017 and based in Allston, Massachusetts, DeepBiome Therapeutics is a biotechnology company focused on revolutionizing drug discovery. The company's core mission is to unlock the therapeutic potential of the microbiome through advanced technologies such as deep learning and synthetic biology. DeepBiome offers a cutting-edge drug discovery platform that enables pharmaceutical companies to develop new therapies more efficiently and effectively. Their market focus is primarily on the healthcare and pharmaceutical sectors, aiming to address unmet medical needs through innovative solutions.

DeepBiome Therapeutics has garnered attention from notable investors and industry experts, contributing to its rapid growth and recognition in the biotech field. The company has achieved significant milestones, including the successful development of its proprietary platform and partnerships with leading drug companies. Its impact is evident in the advancement of microbiome-based therapies, positioning DeepBiome as a key player in the next generation of drug discovery and development.

DeepBiome Therapeutics - Quick Facts

When was DeepBiome Therapeutics founded?

DeepBiome Therapeutics was founded in 2017.

Where is DeepBiome Therapeutics' headquarters located?

DeepBiome Therapeutics' headquarters is located in Llanura, MA, US.

When was DeepBiome Therapeutics' last funding round?

DeepBiome Therapeutics' most recent funding round was for $2.5M (USD) in July 2019.

How much has DeepBiome Therapeutics raised to-date?

As of Jul 26, 2019, DeepBiome Therapeutics has raised a total of $2.5M (USD).

How many employees does DeepBiome Therapeutics have?

DeepBiome Therapeutics has 6 employees as of Feb 5, 2024.

DeepBiome Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
  • Machine Learning
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541500Computer Systems Design and Related Services
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 8000Health Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7371Computer Programming Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified